

Aging with HIV: focus on CNS







Objective:

- to highlight the unmet needs of an ageing HIV population from a clinical and community perspective, and how service provision needs to change to address them
- To critically discuss the applicability of geriatric research tool in HIV research

Headings

- Epidemiological surveillance
- Prevention
- The ageing trajectories
- Multi-Component Interventions
- Health care provision

Headings


- Epidemiological surveillance
- Prevention
- The ageing trajectories
- Multi-Component Interventions
- Health care provision

Life expectancy close to normal population Will this be true in a rapidly changing population?

✓ These projections assume that the risk of mortality in the relatively small proportion of older individuals in contemporary cohort studies will reflect the risk actually observed in the future population ✓ Survival bias: the current older population of HIV-infected individuals survived the pre-ART and early ART eras and may well be enriched for favourable host genetics and healthier lifestyles than the general population.

Estimated number of persons living with HIV aged ≥50 by region (1995-2013)

Africa



- ✓ There are approximately 4.2 million persons aged ≥50y living with HIV today.
- ✓ More than 2 million of which live in sub-Saharan Africa.

America

Headings

- Epidemiological surveillance
- Prevention
- The pathway from disease to disability
- Multi-Component Interventions
- Health care provision

Graying of AIDS

Show Some Skin for a Great Cause!





Headings

- Epidemiological surveillance
- Prevention
- The ageing trajectories
- Multi-Component Interventions
- Health care provision

Male a

Frailty












65 years

In the general population a 60 to 85% increase of fat mass, predominantly represented by visceral adiposity (VAT), is expected between 25 and 65 years of age; in the same period there is a 20% decline of skeletal muscle mass.

PATIENT AGEING TRAJECTORY 2000 2005 2010 2013 2015 Frailty Disability Drug toxicities Co-morbidities Multi-morbidities 2002 2011 2015 HIV






Was there a contribution of HIV and of drug toxicities?

Does HIV causes accelerated or accentuated risk of? A two sided perspective

- 1. To improve overall health and quality of life of a frail HIV individual:
- ✓ Screen
- √ Recognise
- ✓ Treat

HIV is associated with an increased risk of multimorbidity and mortality, which is likely to take on increasing public health importance as the HIV

epidemic gets older.



- 2. To identify target for intervention to prevent multimorbidity and frailty in HIV infection:
- ✓ Identify HIV specific mechanism

Although the clinical phenotype of HIV-associated multimorbidity shares many features with ageing-related frailty, its root causes may in fact be distinct, requiring different interventions for prevention.

Hunt PW. Curr Opin HIV AIDS. 2014 Jul;9(4):302-8.

PATIENT AGEING TRAJECTORY

2000


2005


2010

Drug toxicities Co-morbidities Multi-morbidities



Prevalence of comorbidities and multimorbidity increases with age







In the Modena cohort: Multimorbidity prevalence in those aged 51-60 years was 20%1 In the AgeHIV cohort: Multimorbidity prevalence was 40%2 Multimorbidity prevalence was higher in cases than controls in all age strata

Future challenges for clinical care of an ageing population infected with HIV: a modelling study



Mikaela Smit, Kees Brinkman, Suzanne Geerlings, Colette Smit, Kalyani Thyagarajan, Ard van Sighem, Frank de Wolf, Timothy B Hallett, on behalf of the ATHENA observational cohort





PATIENT AGEING TRAJECTORY

2000 2005 2010 2013

Drug toxicities Co-morbidities Multi-morbidities Frailty



Frailty has been proposed as a measure of biological (opposed to chronological) aging



83 years old; HTN, Hyperlipidemia, prior MI



83 years old; HTN, Hyperlipidemia, prior MI

This variable vulnerability among people of the same chronological age is known as **frailty**



JAMDA




journal homepage: www.jamda.com

Special Article

Frailty Consensus: A Call to Action

John E. Morley MB, BCh ^{a,*}, Bruno Vellas MD ^{b,c}, G. Abellan van Kan MD ^{b,c}, Stefan D. Anker MD, PhD ^{d,e}, Juergen M. Bauer MD, PhD ^f, Roberto Bernabei MD ^g, Matteo Cesari MD, PhD ^{b,c}, W.C. Chumlea PhD ^h, Wolfram Doehner MD, PhD ^{d,i}, Jonathan Evans MD ^j, Linda P. Fried MD, MPH ^k, Jack M. Guralnik MD, PhD ^l, Paul R. Katz MD, CMD ^m, Theodore K. Malmstrom PhD ^{a,n}, Roger J. McCarter PhD ^o, Luis M. Gutierrez Robledo MD, PhD ^p, Ken Rockwood MD ^q, Stephan von Haehling MD, PhD ^r, Maurits F. Vandewoude MD, PhD ^s, Jeremy Walston MD ^t

"...A medical syndrome with multiple causes and contributor that is characterized by diminished strength, endurance and reduced physiologic function that increases an individual's vulnerability for developing increased dependency and/or death..."




Frailty implication for clinical practice





Risk prediction

Trajectories of changes in the health status (Health transitions)



Fried LP, Walston J. Failure to thrieve.

In: Hazzard WR et al, eds. Principles of Geriatric Medicine and Gerontology. McGraw-Hill, 1998

Frailty recognition in clinical practice



Frailty Related Phenotype

A person can be said to be frail if they have any 3 of the following features:

- 1. They move slowly.
- 2. They have a weak handgrip.
- 3. They have reduced their level of activity.
- 4. They have (unintentionally) lost weight.
- 5. They feel exhausted.
- √ "pre-frail" is used when only one or two of these deficits is present.
- ✓ Clinically recognizable and not otherwise definable as being disabled or as having multiple co-morbid illnesses

Frailty recognition in clinical practice



Fried et al., J Gerontol Med Sc 2001

Frailty as a deficit accumulation

Frailty can be operationalized as deficit accumulation and can be expressed in a frailty index

A frailty index derived from routinely collected clinical data can offer insights into the biology of aging using mathematics of complex systems

Can be summarised as a scale from robust to terminally III

Research article A standard procedure for creating a frailty index Samuel D Searle¹, Arnold Mitnitski^{1,2,3}, Evelyne A Gahbauer⁴, Thomas M Gill⁴ and Kenneth Rockwood*^{1,2,5}

BRIEF METHODOLOGICAL REPORTS

Relative Fitness and Frailty of Elderly Men and Women in Developed Countries and Their Relationship with Mortality

Arnold Mitnitski, PhD, $^{\$}$ Xiaowei Song, PhD, * Ingmar Skoog, PhD, MD, $^{\#}$ GA Broe, MBBS, $^{\$}$ Jafna L. Cox, MD, † Eva Grunfeld, MD, ‡ and Kenneth Rockwood, MD*

Variables can be included in a frailty index if they are deficits:

Can include measures of any health problems ("deficits") as long as:

- ✓ Related to age
- ✓ Related to poor health
- As a group, include multiple physiological systems
- ✓ As a group, should number at least around 30

The frailty index approach is robust across different settings, in different populations, using different numbers and types of health variables, consistently related to age and to adverse outcomes.

BMC Geriatrics 2008, 8:24

J Am Geriatr Soc 53:2184–2189, 2005.

The frailty phenotype and the frailty index: different instruments for different purposes

Matteo Cesari^{1,2}, Giovanni Gambassi³, Gabor Abellan van Kan^{1,2}, Bruno Vellas^{1,2}

Main characteristics of the frailty phenotype and the Frailty Index

Frailty phenotype	Frailty Index					
Signs, symptoms	Diseases, activities of da					
	of a clinical evaluation					
Possible before a clinical	Double only after a com					

Possible before a clinical
assessment
Categorical variable
Pre-defined set of criteria
Frailty as a pre-disability syndrome
Meaningful results potentially
restricted to non-disabled older
persons

Diseases, activities of daily living, results of a clinical evaluation

Doable only after a comprehensive clinical assessment

Continuous variable

Unspecified set of criteria

Frailty as an accumulation of deficits

Meaningful results in every individual, independently of functional status or age

Key points:

- ✓ The frailty phenotype may be more suitable for an immediate identification of nondisabled elders at risk of negative events.
- ✓ The Frailty Index may summarise the results of a compre- hensive geriatric assessment providing a marker of deficits accumulation.
- ✓ The two instruments have different purposes and are to be considered complementary in the evaluation of the older person.

Age and Ageing 2013; 0: 1–3



Gérontopôle Frailty Screening Tool (GFST)


Patients aged 65 years and older without both functional disability (Activities of Daily Living score ≥5/6) and current acute disease.

	YES	NO	Do not know
Does your patient live alone?			
Has your patient involuntarily lost weight in the last 3 months?			
Has your patient been more fatigued in the last 3 months?			
Has your patient experienced increased mobility difficulties in the last 3 months?			
Has your patient complained of memory problems?			
Does your patient present slow gait speed (i.e., >4 seconds to walk 4 meters)?			
If you have answered YES to one or more of these questions:			
Do you think your patient is frail?	YES 🗆		<i>NO</i> □
If YES , is your patient willing to be assessed for his/her frailty status at the Frailty Clinic?	YES 🗆		NO □

Original Investigation

Effect of Structured Physical Activity on Prevention of Major Mobility Disability in Older Adults The LIFE Study Randomized Clinical Trial






CONCLUSIONS AND RELEVANCE

A structured, moderate-intensity physicalactivity program compared with a health education program reduced major mobility disability over 2.6 years among older adults at risk for disability.

These findings suggest mobility benefit from such a program in vulnerable older adults

Age, Comorbidities, and AIDS Predict a Frailty Phenotype in Men Who Have Sex With Men

Keri N. Althoff, Lisa P. Jacobson, Ross D. Cranston, Roger Detels, John P. Phair, Xiuhong Li, and Joseph B. Margolick; for the Multicenter AIDS Cohort Study (MACS)



Factors associated with frailty-related phenotype (FRP) to predict MORTALITY in HIV-positive individuals on HAART

HIV-related measures

- Longer time since diagnosis (Aging!)
- AIDS diagnosis
- Lower current CD4 count
- Lower nadir CD4 count
- Low CD4/CD8 ratio
- Detectable viral load
- Protease inhibitor-containing HAART regimen

Social factors

- Smoke
- Current unemployment
- Low income in past year
- College degree

• Age


- Hepatitis C coinfection
- Low BMI

Comorbidities

- High BMI
- Lipodystrophy
- Depressive symptoms
- T2DM
- CKD
- Cognitive impairment
- Inflammation
- Weak upper and lower extremities

Terzian AS, J Womens Health (Larchmt), 2009;18(12):1965-1974. **Onen** NF. J Infect, 2009;59(5):346-352. **Piggott** DA. PloS One, 2013;8(1):e54910. **Ianas** V. J Int Assoc Provid AIDS Care, 2013;12(1):62-66. **Pathai** S, JAIDS 2013;62(1):43-51. **Erlandson** KM. HIV Clin Trials, 2012;13(6):324-334. **Shah** K. J Am Geriatr Soc, 2012; Mar;60(3):545-549. **Justice** AC, JAIDS, 2013;62(2):149-163. **Adeyemi** O, JAIDS 2013;63(2):e78-e81.

Hypothetical association between frailty, HANA and immune activation / inflammation



Mr. X case study

To what extent Pt Age changes our clinical practice?



25 yrs CD4=250µL VL=73000/mL

Naive

45 yrs CD4=650µL VL<40/mL

Experienced


65 yrs CD4=250µL VL=73000/mL

Naive

75 yrs CD4=650µL VL<40/mL

Experienced

Hypothetical association between frailty, HANA and immune activation / inflammation



Prevalence of Frialty

Age

Frailty Index at MHMC

We constructed a Frailty Index (FI) from health variables collected as part of routine assessments in an HIV clinic

No.	Variable
1	Lipoatrophy
2	Lipohypertrophy
3	Non-alcoholic fatty liver disease
4	Menopause or male
4	hypogonadism
5	High or low body mass index
6	High waist circumference
7	High visceral adipose tissue
8	Sarcopenia or presarcopenia
9	Insulin resistance
10	High total cholesterol
11	High low density lipoprotein
12	Low high density lipoprotein
13	High triglycerides
14	High homocysteine
15	Abnormal white blood cell counts
16	Anemia
17	Hepatitis C co-infection
18	Hepatitis B co-infection
19	Vitamin D insufficiency
20	Polypharmacy

21	Abnormal parathyroid hormone
22	Elevated D-dimer
23	Elevated C-reactive protein
24	Sedentary lifestyle
25	Atherosclerosis
26	Hyponatremia
27	Proteinuria or albuminuria
28	Elevated aspartate transaminase
	(AST)
29	Elevated alanine transaminase
	(ALT)
30	Abnormal alkaline phosphatase
31	Elevated gamma-glutamyl
	transphosphatase (GGT)
32	Low platelets
33	Abnormal potassium
34	Abnormal phosphorus
35	Abnormal thyroid stimulating
	hormone
36	Elevated total bilirubin
37	Unemployment

Frailty Index use at Modena HIV Metabolic Clinic



Male 80 years CD4=701 HIV VL<40 c/ mL

IMA, HTN T2DM OO Cirrhosis

Male 83 years CD4=661 HIV VL<40 c/mL


IMA OO

Visita		G	GIUSEPPE		07/04/1935	Anagrafica	Vis	sita		CARLO		29/09/1932	Anagrafica
	Data Es:	HIVFI (>.4):	HIVMMFL (>.4):	FI (>.39):	MMFI (>.37):	Deficit:		Data Es:	HIVFI (>.4):	HIVMMFL (>.4):	FI (>.39):	MMFI (>.37):	Deficit:
•	20/05/2014	0,4693878	0,4418605	0,4883721	0,4594595	23		11/11/2013	0,2708333	0,2380952	0,3023256	0,2702703	13
	11/12/2012	0,4705882	0,4444444	0,5116279	0,4864865	24		24/09/2012	0,2857143	0,255814	0,33333333	0,3055556	14
	13/12/2011	0,509804	0,4666667	0,5581396	0,5135135	26		20/09/2011	0,22	0,1818182	0,255814	0,2162162	11
	13/12/2010	0,3921569	0,3555556	0,3953488	0,3513514	20		07/09/2010	0,24	0,2045455	0,2790698	0,2432432	
	15/03/2010	N 3877551	U 3838384	0.4146341	U 388888a	10		04/ <u>06/2</u> 010					q


Frailty Index in routine clinical management:

- ✓ Comprehensive evaluation of clinical visit
- ✓ Evaluation of health transition
- ✓ Time interval of Follow Up visits
- / Hama has hadth agra provision

Hypothetical association between frailty, HANA and immune activation / inflammation




Frailty index predicts survival independently from markers of HIV disease severity among people ageing with HIV



33 deaths over 8150 person-years follow-up (mortality rate; 0.40/100 PYFU)


Frailty index predicts incident multimorbidity independently from markers of HIV disease severity among people ageing with HIV

Poisson analyses to predict Mm



228 (9.4%) new MM over 6925 person-years follow-up (incident rate 3.29/100 PYFU)

PATIENT AGEING TRAJECTORY



MAJOR ARTICLE

Association of Functional Impairment with Inflammation and Immune Activation in HIV Type 1–Infected Adults Receiving Effective Antiretroviral Therapy

Kristine M. Erlandson, 12 Amanda A. Allshouse, 3 Catherine M. Jankowski, 2 Eric J. Lee, 1 Kevin M. Rufner, 4 Brent E. Palmer, 5 Cara C. Wilson, 1 Samantha MaWhinney, 3 Wendy M. Kohrt, 2 and Thomas B. Campbell 1

AIDS RESEARCH AND HUMAN RETROVIRUSES Volume 29, Number 00, 2013 ® Mary Ann Liebert, Inc. DOI: 10.1089/aid 2013.0020

> Lipodystrophy and Inflammation Predict Later Grip Strength in HIV-Infected Men: The MACS Body Composition Substudy

Keith W. Crawford, Xiuhong Li, Xiaoqiang Xu, Alison G. Abraham, Adrian S. Dobs, Joseph B. Margolick, Frank J. Palella, Lawrence A. Kingsley, Mallory D. Witt, and Todd T. Brown

Headings

- Epidemiological surveillance
- Comorbidities
- Prevention
- The ageing trajectories
- Multi-Component Interventions
- Health care provision

EMPOWERMENT: Wellness checklist

Daily


- 1. Could I exercize more today?
- 2. Have I bought the right food?
- 3. Should I drink less alcohol today?
- 4. Am I doing the right thing to help me sleep properly?
- 5. Am I doing something new today?
- 6. Am I keeping my brain active?

Weekly

- 1. Am I doing something nice with a friend this week?
- 2. What is my weight and is it changing?
- 3. Have I planned an active weekend?
- 4. Am I eating healthy?

Every three to four months

- 1. Do I feel well or unwell?
- 2. Have I had my checkup at the clinic?
- 3. What are my blood results?
- 4. Have I stopped smoking?
- 5. Are my finances in order?
- 6. How has my mood been recently?
- 7. What are my plans for the next few months?




Future challenges for clinical care of an ageing population infected with HIV: a modelling study




Mikaela Smit, Kees Brinkman, Suzanne Geerlings, Colette Smit, Kalyani Thyagarajan, Ard van Sighem, Frank de Wolf, Timothy B Hallett, on behalf of the ATHENA observational cohort

Predicted burden of co-medications in HIV-infected patients between 2010 and 2030.



Predicted prevalence of comedication in 2030 as crosssection of number of patients on the different types of co-medications, based on a representative 400 patients (each square represents a patient). NCD=noncommunicable disease.



Novel concept in handling of HIV+ persons on stable ART at HIV clinics

- Comprehensive care of HIV+ persons involves:
 - Handling HIV-specific issues
 - General medicine due to age related co-morbidities
 - Multidisciplinary approach
- Diversification of type of visits
 - Traditional f2f visit with responsible physician
 - Triage with experienced nurse
 - Community clinic
 - Telemedicine (for most stable patients)
- Enhancing self management
- Focus areas
 - Ensure retainment in care
 - Shared access to electronic systems (lab, medicine) to allow for proactive alert and prompts

HIV specialist physicians have to continue to lead the way to ensure optimization of quality of care for HIV+ persons

Take home message

- FI is applicable in clinical practice to describe health transition and suitable to depict the impact of ARV strategies in ageing trajectories
- Frailty is a significant mediator & moderator of the relationship between MM and Disability
- Both cognitive impairment and Depression are predictors of Frailty but the Depression moderate the impact of Cognitive impairment on Frailty
- Life style intervention and ARV strategies need to be integrated in the management of Senior HIV patients

Clinical suggestion:

 Diagnosis and treatment of depression is likely to be the most effective intervention to reduce the burden of Frailty and Disability



Thank you....
...and stay fit!